Industry reports · 43 reports
Biotechnology Pharmaceuticals industry statistics
Market size, growth, leading companies and trends for 43 industries in biotechnology pharmaceuticals. Each report links every figure to its source.
Industry report
503B Industry
Industry report
Active Pharmaceutical Ingredient Industry
Industry report
AI Pharmaceutical Industry
AI is shaving months off every stage from target finding to trials, with recruitment time cut 75% by ML matching and Phase 1 failure dropping from 30% to 15% across 20 pharma collaborations. At the same time, the pipeline is accelerating at an industrial pace, with AI drug discovery projected to reach USD 11.9 billion by 2033 and pharma startups raising over USD 4.5 billion in 2023 while regulators tighten validation expectations.
Industry report
Algae Industry
Algae Industry’s latest statistics lay out how fast production is shifting, with 2025 and 2026 figures that reveal where capacity is really heading. See the surprising gaps between scale, adoption, and market pull so you can spot which algae applications are gaining momentum next.
Industry report
Animal Testing Cosmetic Industry
Industry report
Antibiotic Industry
Industry report
Bio Healthcare Industry
Oncology trials drove 38% of biotech’s 2023 studies—explore the Bio Healthcare Industry stats behind what’s moving fastest.
Industry report
Bio Industry
Bioeconomy market size reached $307.3B in 2022—while biopharma funding fell 11% YoY in 2023. Explore the signals shaping bio industry investment.
Industry report
Bio Tech Industry
Industry report
Bio Technology Industry
Industry report
Biologics Industry
Industry report
Biomedical Industry
Gene and device breakthroughs keep accelerating, but the bottlenecks are getting sharper, with 2024 showing 2,000 plus net clinical trial registrations added every week to ClinicalTrials.gov and 15 percent of FDA device inspections ending in warning letters. If you want the pulse of where biopharma and medical technology momentum is colliding with safety, compliance, and operational speed, this page brings those tradeoffs into one tightly quantified snapshot.
Industry report
Biopharmaceutical Industry
Phase III trials cost about $255M per drug on average in 2023—see what drives the industry’s investment pipeline.
Industry report
Bioprocessing Industry
See how 2026 projections are reshaping expectations for bioprocessing scale up and investment, with demand and capacity trends moving faster than many operational models. The page sets side by side the headwinds and momentum across the value chain so you can gauge where throughput, costs, and process performance are likely to converge next.
Industry report
Bioscience Industry
Industry report
Biosimilar Industry
Industry report
Biotech Healthcare Industry
Fresh 2026 indicators in biotech and healthcare show how quickly R and D, funding, and clinical momentum are shifting compared with the prior cycles that shaped strategy. If you want to understand where investment and innovation are actually concentrating right now, these statistics are the clearest place to spot the change.
Industry report
Biotech Industry
With 2025 headwinds and 2026 momentum shaping biotech investment and trials, this page highlights the sharp contrasts between where funding is flowing and where R and D outcomes are landing. If you want the most current signals on how quickly the industry is shifting, these statistics make the pattern hard to ignore.
Industry report
Biotech Pharma Industry
Biotech and biopharma are accelerating fast as the global biotechnology market is projected to hit $1.26 trillion by 2030 and CDMO growth is forecast at 4.1% annually through 2032. At the same time, investors put $91.0 billion into biotech in 2021 and the FDA keeps tilting approvals toward biologics, making these supply chain and regulatory signals impossible to ignore for anyone tracking what is next in drug development.
Industry report
Biotechnology And Pharmaceutical Industry
Industry report
Biotechnology Healthcare Industry
U.S. biotech VC funding hit USD 35B in 2023—down 30% from the 2022 peak. Explore what’s fueling the next approvals.
Industry report
Biotechnology Industry
With the global biotechnology market forecast to grow at a 6.8% CAGR from 2024 to 2032, and U.S. biomanufacturing demand projected to rise 6.5% through 2027, this page puts growth beside the real-world frictions that slow therapies from lab to patient. Expect striking cost and timeline contrasts, like a median 5.2 years for FDA innovative-therapy clinical trials and sterile cleanroom needs at ISO 5, alongside hard regulatory throughput and biosimilars momentum.
Industry report
Biotechnology Pharmaceutical Industry
Women account for 52% of the U.S. biotech workforce in 2023 while STEM workers make up 75% of all roles, even as turnover averages 12.5% and remote work climbs to 28% of operations. From 2023 funding bursts and FDA approvals led by biotech to a global workforce that tops 1.2 million with 40% in R and D, these statistics map where talent, capital, and manufacturing capacity are shifting next.
Industry report
Cdmo Industry
CDMO Industry’s latest stats show how quickly 2026 priorities are reshaping outsourcing decisions, with demand and capacity signals moving in opposite directions that many teams did not expect. The result is a clearer view of where contract manufacturing is tightening and where new room is opening for sponsors.
Industry report
Chinese Pharmaceutical Industry
Industry report
Clinical Research Organization Industry
With the global CRO market still projected to grow at a 7.4% CAGR from 2023 to 203..., and Asia Pacific forecast to post the fastest 9.1% CAGR through 2030, the balance of clinical outsourcing is shifting fast, from North America’s 39.2% revenue share in 2022 to Asia’s accelerating trial pipeline. See how operational upgrades like AI and decentralized trials are already cutting timelines and improving retention while leading vendors such as IQVIA, ICON, and PPD continue to widen the competitive gap.
Industry report
Clinical Trials Industry
In 2019, the FDA issued 4,173 warning letters—what that means for compliance and participant safety in clinical trials today.
Industry report
Cmc Industry
Industry report
Cmt Industry
Industry report
Data Integrity Pharmaceutical Industry
Industry report
Dna Sequencing Industry
The DNA sequencing market is projected to grow at a 10.7% CAGR through 2032, with global revenue rising from $9.3 billion in 2023 to $11.0 billion in 2024, and NGS scaling toward $17.6 billion by 2030. You will see how cost drivers, throughput, and instrument versus consumables spend shape per-genome economics alongside real-world momentum from programs like the UK NHS Genomic Medicine Service and large-scale cohorts.
Industry report
Dna Testing Industry
With the global DNA testing services market climbing from $9.6 billion in 2023 to a projected $17.9 billion by 2030, this page connects the spending surge to the real test performance and turnaround expectations that clinics and labs must meet, from 7 to 14 day clinical panel workflows to validated NGS specificity near 99%. You will also see how rapidly costs are falling, including whole genome sequencing list prices dropping from about $2,000 to under $1,000 by 2020 to 2021, alongside privacy and regulatory pressure that keeps reshaping what gets tested and how.
Industry report
Environmental Monitoring Pharmaceutical Industry
Industry report
Fermentation Industry
Global fermentation ingredients reached USD 52.3 billion in 2023 and are projected to climb to USD 78.6 billion by 2032, but the real story is how regional power and process breakthroughs are reshuffling supply chains, from China’s 65% share of citric acid fermentation to EU breweries cutting 1.2 million tons of emissions with CO2 capture. Follow the figures behind everything from soy sauce and kimchi volumes to the shift toward continuous fermentation, enzyme cost cuts, and precision methods that are changing what scale means for fermentation plants in 2025 and beyond.
Industry report
Genomics Industry
Industry report
Lifescience Industry
Industry report
Market Access Pharmaceutical Industry
Industry report
Obesity Drug Industry
Trials and sales reporting through 2025 paint an efficiency gap hard to ignore: tirzepatide hits 26.6% total weight loss in SURMOUNT-3 after lifestyle alone and selected cardiovascular data pair with faster weight durability, while Wegovy reached $2.6 billion in U.S. H1 2024 sales and total GLP-1 spend reached $18.5 billion in 2023. This page turns those headline results into a clear industry scoreboard from 15% loss with semaglutide STEP 1 to 22.5% with tirzepatide SURMOUNT-2 in type 2 diabetes and beyond, including what payers, side effect signals, and next generation oral and dual agonists are likely to change next.
Industry report
Peptide Industry
Peptide drug development still hits a 15 to 30% clinical failure rate from PK PD and stability problems even as the pipeline accelerates with 10,290 peptide trials registered on ClinicalTrials.gov in 2023. See how the market is pushing forward to a projected $64.5 billion by 2030 alongside real manufacturing pressure points such as analytical release costs and CGMP related warning letter findings that can make or break batches.
Industry report
Pharmaceutical Industry
From 55 novel drugs approved by the FDA in 2023 to a global pharmaceutical market valued at $1.48 trillion in 2023, the industry’s momentum is clear, even as U.S. drug prices sit 2.56 times higher than in other high-income countries. This page connects the people and the politics behind the $200 billion in 2022 global R and D, showing how everything from Pfizer’s 2023 revenue and workforce to 1,205 U.S. patent disputes in 2022 helps shape what patients pay and what gets approved.
Industry report
Pharmaceutical Manufacturing Industry
In 2026, Pharmaceutical Manufacturing Industry stats point to a faster pace of capacity expansion and a sharper tightening of quality expectations, with costs and throughput moving in opposite directions. If you work across operations, compliance, or supply chain, these figures will help you spot where the industry is gaining speed and where it is paying for it.
Industry report
Pharmacuetical Industry
Industry report
Synthetic Biology Industry
With 2023’s regulatory updates across EU advanced therapy and GM rules running alongside 1.2M+ synthetic biology related sequences added to GenBank since 2018, this page tracks how faster design is meeting tighter oversight. It pairs practical lab performance like 20–60% fermentation time reductions and 20–30% expected yield gains with biosafety and TEA constraints, plus market signals such as 35.7% CAGR and 6% of biotech market cap in public synthetic biology stocks.